Citations

Showing 10 of 108119 citations.

Ceftriaxone-induced leucocytoclastic vasculitis
Haehn, Daniela A. , Patel, Archi, Youngberg, George A. , Gonzalez‐Estrada, Alexei , Haehn, Daniela Andrea, Gonzalez-Estrada, Alexei

Mayo Clinic

BMJ Case Reports | April 15, 2019 | Volume: 12 | Issue: 4 | Pages: e229411

10.1136/bcr-2019-229411 | PMID 30988110 Get It

Low Ureaplasma Polymerase Chain Reaction Positivity Rate Among Newborns in a Neonatal Intensive Care Unit or Intermediate Special Care Nursery
Madigan, Theresa , Carey, William A., Kaemingk, Bethany D. , Patel, Robin , Patel, Robin

Mayo Clinic

Pediatric Infectious Disease Journal | April 15, 2019 | Volume: 38 | Issue: 5 | Pages: e111-e111

10.1097/inf.0000000000002275 | PMID 30985550 Get It

The Mediating Effect of Pain Catastrophizing on PTSD Symptoms and Pain Outcome
Gilliam, Wesley P. , Craner, Julia R. , Schumann, Matthew E. , Gascho, Keith

Mayo Clinic

The Clinical Journal of Pain | April 15, 2019 | Volume: 35 | Issue: 7 | Pages: 583-588

10.1097/ajp.0000000000000713 | PMID 30950871 Get It

Objective: Coprevalence of chronic pain and posttraumatic stress disorder (PTSD) negatively impacts the course of both disorders. Patients diagnosed with both conditions report greater pain, affective distress, and disability when compared with those with either chronic pain or PTSD alone. While the prevalence and complexity of the comorbidity is widely acknowledged, there is a dearth of research examining potential mechanism variables that might account for the relationship between chronic pain and PTSD. The current study utilizes a series of mediation analyses to examine if pain catastrophizing mediates the relationship between PTSD symptomatology and chronic pain outcome. Materials and Methods: A total of 203 treatment-seeking participants admitted to a 3-week interdisciplinary pain rehabilitation program completed a battery of psychometrically validated measures of pain severity, pain interference, pain catastrophizing, depressive symptoms, and PTSD symptoms at program admission. Results: A series of multiple parallel mediation analyses revealed that pain catastrophizing fully mediated the relationships between PTSD symptoms and pain outcome (ie, pain severity and pain interference) above and beyond the influence of depressive symptoms. Discussion: Results suggest that pain catastrophizing may represent an important cognitive mechanism through which PTSD symptoms influence the experience of chronic pain. Psychosocial treatment approaches that directly target tendency to catastrophize in response to pain may hold the potential to have salutary effects on both chronic pain and PTSD.
Targeted Biopsy Validation of Peripheral Zone Prostate Cancer Characterization With Magnetic Resonance Fingerprinting and Diffusion Mapping
Panda, Ananya , O’Connor, Gregory , Lo, Wei Ching, Jiang, Yun , Schluchter, Mark , Ponsky, Lee , Gulani, Vikas , Margevicius, Seunghee Park

Mayo Clinic

Investigative Radiology | April 15, 2019 | Volume: 54 | Issue: 8 | Pages: 485-493

10.1097/rli.0000000000000569 | PMID 30985480 Get It

Objective This study aims for targeted biopsy validation of magnetic resonance fingerprinting (MRF) and diffusion mapping for characterizing peripheral zone (PZ) prostate cancer and noncancers. Materials and Methods One hundred four PZ lesions in 85 patients who underwent magnetic resonance imaging were retrospectively analyzed with apparent diffusion coefficient (ADC) mapping, MRF, and targeted biopsy (cognitive or in-gantry). A radiologist blinded to pathology drew regions of interest on targeted lesions and visually normal peripheral zone on MRF and ADC maps. Mean T1, T2, and ADC were analyzed using linear mixed models. Generalized estimating equations logistic regression analyses were used to evaluate T1 and T2 relaxometry combined with ADC in differentiating pathologic groups. Results Targeted biopsy revealed 63 cancers (low-grade cancer/Gleason score 6 = 10, clinically significant cancer/Gleason score ≥7 = 53), 15 prostatitis, and 26 negative biopsies. Prostate cancer T1, T2, and ADC (mean ± SD, 1660 ± 270 milliseconds, 56 ± 20 milliseconds, 0.70 × 10−3 ± 0.24 × 10−3 mm2/s) were significantly lower than prostatitis (mean ± SD, 1730 ± 350 milliseconds, 77 ± 36 milliseconds, 1.00 × 10−3 ± 0.30 × 10−3 mm2/s) and negative biopsies (mean ± SD, 1810 ± 250 milliseconds, 71 ± 37 milliseconds, 1.00 × 10−3 ± 0.33 × 10−3 mm2/s). For cancer versus prostatitis, ADC was sensitive and T2 specific with comparable area under curve (AUC; (AUCT2 = 0.71, AUCADC = 0.79, difference between AUCs not significant P = 0.37). T1 + ADC (AUCT1 + ADC = 0.83) provided the best separation between cancer and negative biopsies. Low-grade cancer T2 and ADC (mean ± SD, 75 ± 29 milliseconds, 0.96 × 10−3 ± 0.34 × 10−3 mm2/s) were significantly higher than clinically significant cancers (mean ± SD, 52 ± 16 milliseconds, 0.65 ± 0.18 × 10−3 mm2/s), and T2 + ADC (AUCT2 + ADC = 0.91) provided the best separation. Conclusions T1 and T2 relaxometry combined with ADC mapping may be useful for quantitative characterization of prostate cancer grades and differentiating cancer from noncancers for PZ lesions seen on T2-weighted images.
The Clinical Spectrum of New-Onset Status Epilepticus
Chakraborty, Tia , Hocker, Sara E.

Mayo Clinic

Critical Care Medicine | April 15, 2019 | Volume: 47 | Issue: 7 | Pages: 970-974

10.1097/ccm.0000000000003776 | PMID 30985452 Get It

Objectives: There is a paucity of data on patients with new-onset status epilepticus in patients without a prior history of epilepsy; we aimed to describe clinical characteristics and assess variables predictive of outcomes. Design: Retrospective cohort. Setting: Quaternary academic medical center. Patients: Adult patients with new-onset status epilepticus. Methods: Retrospective review of adults with new-onset status epilepticus admitted to Mayo Clinic, Rochester MN between January 1, 1990, and December 31, 2015, was performed. Patient demographics, status epilepticus etiology, Status Epilepticus Severity Score, and status epilepticus classification per the Status Epilepticus Severity Score were recorded. Six-month mortality and functional outcomes defined as modified Rankin scale (≥3 at last follow-up was considered poor) were primary outcomes. Refractory status epilepticus was a secondary outcome. Interventions: None. Measurements and Main Results: One-hundred seventy-seven patients were included. Status epilepticus was convulsive in 124 (70.1%) and nonconvulsive in 53 (29.9%); 96 cases (54.2%) were refractory status epilepticus. Mean age at onset was 63 ± 18 years; 52.5% were greater than or equal to 65 years. Etiologies were acute in 50.8%, progressive in 18.1%, remote in 19.2%, and unknown in 11.9% patients. Six-month mortality was 32.2%, and 70.1% had poor modified Rankin scale at mean follow-up 3.1 ± 3.5 years. Age greater than or equal to 65 was a significant predictor of poor functional outcome and 6-month mortality. Loss of consciousness, status epilepticus classification, or age greater than or equal to 65 did not predict progression to refractory status epilepticus. Progression to refractory status epilepticus did not impact functional outcome or mortality at last follow-up. Conclusions: Poor outcomes in new-onset status epilepticus were associated with older age as well as predominantly progressive or remote symptomatic disease. Further prospective investigations assessing the course and outcomes of these patients would be useful in management and prognostication.
Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease
Novak, Gregor , Stevens, Toer , Viegen, Tanja van, Bossuyt, Peter , Štabuc, Borut, Jeyarajah, Jenny , Zou, Guangyong , Gaemers, Ingrid C., McKee, Trevor D. , Fu, Fred , Shackelton, Lisa M. , Khanna, Reena , Sandborn, William J. , Feagan, Brian G. , Pai, Rish K. , D’Haens, Geert , Sandborn, W J , Feagan, B G , Vande Casteele, N , BRINK, Gijs R. VAN DEN , Jairath, Vipul , Casteele, Niels Vande , Zou, Guangyong , Bossuyt, Peter

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 15, 2019 | Volume: 49 | Issue: 11 | Pages: 1401-1409

10.1111/apt.15250 | PMID 30983024 Get It

SummaryBackgroundThe appropriate location for biopsy procurement relative to an ulcer in active Crohn's disease is unknown.AimTo explore the relationship between biopsy location, histological disease activity, proinflammatory gene expression and the presence of inflammatory cells.MethodsFifty‐one patients with Crohn's disease and ulcers >0.5 cm diameter in the colon and/or ileum were prospectively enrolled at three centres. Biopsies were obtained from 0 mm, 7 to 8 mm and 21 to 24 mm from the edge of the largest ulcer. Histological activity was blindly assessed with the Global Histological Disease Activity Score, the Robarts Histopathology and Nancy Histological indices. Messenger ribonucleic acid (mRNA) levels for interleukins‐6, ‐8 and ‐23 (p19 and p40 subunits), CD31 and S100A9 were measured using quantitative polymerase chain reaction. The number of CD3+, CD68+ and myeloperoxidase‐positive cells was quantified by immunohistochemistry. Data were analysed using mixed models with location and segment as fixed effects and patients as random effect to account for correlation among segments within a patient.ResultsHistological disease activity scores (P < 0.0001), proinflammatory gene expression levels (P < 0.005) and numbers of myeloperoxidase‐positive cells (P < 0.0001) were highest in biopsies from the ulcer edge in the colon and ileum, with decreasing gradients observed with distance from the edge (P < 0.05). No differences between colonic and ileal samples were detected for the parameters measured at any location.ConclusionsBiopsies from the ulcer edge in patients with Crohn's disease yielded the greatest histological disease activity and mRNA levels and had similar readouts in the colon and ileum. Research is needed to confirm this conclusion for other measures.
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Chávez, Julio C. , Bachmeier, Christina A. , Kharfan‐Dabaja, Mohamed A. , Chavez, Julio C

Mayo Clinic

Therapeutic Advances in Hematology | April 15, 2019 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/2040620719841581 | PMID 31019670 Get It

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed the treatment landscape of B-cell non-Hodgkin’s lymphoma (NHL), especially for aggressive B-cell lymphomas. Single-center and multicenter clinical trials with anti-CD19 CAR T-cell therapy have shown great activity and long-term remissions in poor-risk diffuse large B-cell lymphoma (DLBCL) when no other effective treatment options are available. Two CAR T-cell products [axicabtagene ciloleucel (axi-cel) and tisagenlecleucel] have obtained US Food and Drug Administration approval for the treatment of refractory DLBCL after two lines of therapy. A third product, liso-cel, is currently being evaluated in clinical trials and preliminary results appear very promising. CAR T-cell-related toxicity with cytokine-release syndrome and neurotoxicity remain important potential complications of this therapy. Here, we review the s biology, structure, clinical trial results and toxicity of two commercially approved CAR T-cell products and others currently being studied in multicenter clinical trials in B-cell NHLs.
Integrated Transcriptomic and Proteomic Analysis of Primary Human Umbilical Vein Endothelial Cells
Madugundu, Anil K. , Na, Chan Hyun , Nirujogi, Raja Sekhar , Renuse, Santosh , Kim, Kwang Pyo , Wilks, Christopher , Langmead, Ben , Collado‐Torres, Leonardo , Kim, Min‐Sik , Pandey, Akhilesh , Kim, Min-Sik , Pandey, Akhilesh , Pandey, Akhilesh , Kim, Kwang Pyo , Burns, Kathleen H , Ellis, Shannon , Halushka, Marc K.

Mayo Clinic

PROTEOMICS | April 15, 2019 | Volume: 19 | Issue: 15 | Pages: No page available

10.1002/pmic.201800315 | PMID 30983154 Get It

Abstract Understanding the molecular profile of every human cell type is essential for understanding its role in normal physiology and disease. Technological advancements in DNA sequencing, mass spectrometry, and computational methods allow us to carry out multiomics analyses although such approaches are not routine yet. Human umbilical vein endothelial cells (HUVECs) are a widely used model system to study pathological and physiological processes associated with the cardiovascular system. In this study, next‐generation sequencing and high‐resolution mass spectrometry to profile the transcriptome and proteome of primary HUVECs is employed. Analysis of 145 million paired‐end reads from next‐generation sequencing confirmed expression of 12 186 protein‐coding genes (FPKM ≥0.1), 439 novel long non‐coding RNAs, and revealed 6089 novel isoforms that were not annotated in GENCODE. Proteomics analysis identifies 6477 proteins including confirmation of N ‐termini for 1091 proteins, isoforms for 149 proteins, and 1034 phosphosites. A database search to specifically identify other post‐translational modifications provide evidence for a number of modification sites on 117 proteins which include ubiquitylation, lysine acetylation, and mono‐, di‐ and tri‐methylation events. Evidence for 11 “missing proteins,” which are proteins for which there was insufficient or no protein level evidence, is provided. Peptides supporting missing protein and novel events are validated by comparison of MS/MS fragmentation patterns with synthetic peptides. Finally, 245 variant peptides derived from 207 expressed proteins in addition to alternate translational start sites for seven proteins and evidence for novel proteoforms for five proteins resulting from alternative splicing are identified. Overall, it is believed that the integrated approach employed in this study is widely applicable to study any primary cell type for deeper molecular characterization.
AAPM—The Multidisciplinary Pain Society
Lamer, Tim J.

Mayo Clinic

Pain Medicine | April 14, 2019 | Volume: 20 | Issue: 7 | Pages: 1259-1261

10.1093/pm/pnz106 | PMID 31099845 Get It

0690 Enlarged Basal Ganglia Perivascular Spaces And Sleep Parameters. A Population-based Study.
Wasey, Waiz, Brutto, Óscar H. Del , Mera, Robertino M. , Brutto, Víctor J. Del , Castillo, Pablo R.

Mayo Clinic

Sleep | April 13, 2019 | Volume: 42 | Issue: Supplement_1 | Pages: A276-A277

10.1093/sleep/zsz067.688 Get It